---
document_datetime: 2025-12-02 05:23:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/cufence.html
document_name: cufence.html
version: success
processing_time: 0.0931316
conversion_datetime: 2025-12-24 00:26:54.121928
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Cufence

[RSS](/en/individual-human-medicine.xml/67223)

##### Authorised

This medicine is authorised for use in the European Union

trientine dihydrochloride Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Cufence](#news-on)
- [More information on Cufence](#more-information-on-cufence-896)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Cufence is a medicine used to treat patients aged 5 years and older with Wilson's disease, a genetic condition in which copper absorbed from food builds up in the body, particularly in the liver and the brain, causing damage. Cufence is used in patients who cannot take D-penicillamine, another medicine for this condition. Cufence contains the active substance trientine dihydrochloride.

Expand section

Collapse section

## How is Cufence used?

Cufence can only be obtained with a prescription and treatment should be started by a specialist with experience in the management of Wilson's disease.

Cufence is available as 200 mg capsules. The recommended daily dose is 4 to 8 capsules in adults, and 2 to 5 capsules in children. The capsules are taken in 2 to 4 divided doses. Doses are adjusted according to patient response and levels of copper in the body. Cufence should be taken on an empty stomach, at least one hour before or two hours after meals.

For more information about using Cufence, see the package leaflet or contact your doctor or pharmacist.

## How does Cufence work?

The active substance in Cufence, trientine, is a chelating agent. It works by attaching to copper in the body and forming a complex that is then eliminated in the urine and faeces.

## What benefits of Cufence have been shown in studies?

The active substance in Cufence, trientine, has been shown to improve symptoms of liver and neurological disease in patients with Wilson's disease who could no longer take D-penicillamine.

In a study of medical records of 77 patients treated with trientine for at least six months, symptoms of liver disease improved in almost half (49%) of the patients treated, and neurological symptoms improved in 14% of the patients. A small proportion of patients had deteriorating symptoms: 5% with worsening liver symptoms and 3% with worsening neurological symptoms.

## What are the risks associated with Cufence?

The most common side effect with Cufence (which may affect up to 1 in 10 people) is nausea (feeling sick), especially when starting treatment. Skin rash may affect up to 1 in 100 people. Duodenitis (inflammation of the duodenum, the part of the gut leading out of the stomach) and severe colitis (inflammation in the large bowel causing pain and diarrhoea) have also been reported. In some patients, neurological deterioration can occur at the start of the treatment, with symptoms such as dystonia (involuntary muscle contractions), stiffness, tremor (shaking) and dysarthria (difficulty speaking).

For the full list of side effects and restrictions of Cufence, see the package leaflet.

## Why is Cufence authorised in the EU?

Trientine has been used for over 30 years to treat patients with Wilson's disease. Although D-penicillamine is the main treatment for this condition, trientine is effective at improving the symptoms of liver and neurological disease in patients who cannot take this medicine. The safety of Cufence has been shown to be similar to that of other trientine medicines.

The European Medicines Agency therefore decided that Cufence's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Cufence?

The company that markets Cufence will conduct a study to further characterise the effectiveness of trientine in the treatment of Wilson's disease, including its effect on the associated liver, neurological or psychiatric symptoms and what the dose should be during early treatment.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cufence have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Cufence are continuously monitored. Side effects reported with Cufence are carefully evaluated and any necessary action taken to protect patients.

## Other information about Cufence

Cufence received a marketing authorisation valid throughout the EU on 25 July 2019.

This overview was last updated in 09-2022.

Cufence : EPAR - Medicine overview

Reference Number: EMA/775669/2022

English (EN) (116.27 KB - PDF)

**First published:** 29/07/2019

**Last updated:** 28/10/2022

[View](/en/documents/overview/cufence-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-404)

български (BG) (140.1 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/bg/documents/overview/cufence-epar-medicine-overview_bg.pdf)

español (ES) (116.51 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/es/documents/overview/cufence-epar-medicine-overview_es.pdf)

čeština (CS) (139.28 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/cs/documents/overview/cufence-epar-medicine-overview_cs.pdf)

dansk (DA) (115.5 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/da/documents/overview/cufence-epar-medicine-overview_da.pdf)

Deutsch (DE) (119.75 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/de/documents/overview/cufence-epar-medicine-overview_de.pdf)

eesti keel (ET) (104.61 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/et/documents/overview/cufence-epar-medicine-overview_et.pdf)

ελληνικά (EL) (140.26 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/el/documents/overview/cufence-epar-medicine-overview_el.pdf)

français (FR) (118.31 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/fr/documents/overview/cufence-epar-medicine-overview_fr.pdf)

hrvatski (HR) (136.72 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/hr/documents/overview/cufence-epar-medicine-overview_hr.pdf)

italiano (IT) (115.08 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/it/documents/overview/cufence-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (134.13 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/lv/documents/overview/cufence-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (137.5 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/lt/documents/overview/cufence-epar-medicine-overview_lt.pdf)

magyar (HU) (134.72 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/hu/documents/overview/cufence-epar-medicine-overview_hu.pdf)

Malti (MT) (140.18 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/mt/documents/overview/cufence-epar-medicine-overview_mt.pdf)

Nederlands (NL) (116.91 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/nl/documents/overview/cufence-epar-medicine-overview_nl.pdf)

polski (PL) (139.49 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/pl/documents/overview/cufence-epar-medicine-overview_pl.pdf)

português (PT) (116.92 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/pt/documents/overview/cufence-epar-medicine-overview_pt.pdf)

română (RO) (143.61 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/ro/documents/overview/cufence-epar-medicine-overview_ro.pdf)

slovenčina (SK) (139.3 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/sk/documents/overview/cufence-epar-medicine-overview_sk.pdf)

slovenščina (SL) (135.67 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/sl/documents/overview/cufence-epar-medicine-overview_sl.pdf)

Suomi (FI) (114.28 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/fi/documents/overview/cufence-epar-medicine-overview_fi.pdf)

svenska (SV) (115.55 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

28/10/2022

[View](/sv/documents/overview/cufence-epar-medicine-overview_sv.pdf)

Cufence : EPAR - Risk management plan

English (EN) (618.75 KB - PDF)

**First published:** 29/07/2019

**Last updated:** 02/07/2025

[View](/en/documents/rmp/cufence-epar-risk-management-plan_en.pdf)

## Product information

Cufence : EPAR - Product information

English (EN) (404.86 KB - PDF)

**First published:** 29/07/2019

**Last updated:** 02/07/2025

[View](/en/documents/product-information/cufence-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-724)

български (BG) (421.61 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/bg/documents/product-information/cufence-epar-product-information_bg.pdf)

español (ES) (440.65 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/es/documents/product-information/cufence-epar-product-information_es.pdf)

čeština (CS) (403.9 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/cs/documents/product-information/cufence-epar-product-information_cs.pdf)

dansk (DA) (374.24 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/da/documents/product-information/cufence-epar-product-information_da.pdf)

Deutsch (DE) (427.79 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/de/documents/product-information/cufence-epar-product-information_de.pdf)

eesti keel (ET) (387.28 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/et/documents/product-information/cufence-epar-product-information_et.pdf)

ελληνικά (EL) (442.36 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/el/documents/product-information/cufence-epar-product-information_el.pdf)

français (FR) (407.87 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/fr/documents/product-information/cufence-epar-product-information_fr.pdf)

hrvatski (HR) (393.35 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/hr/documents/product-information/cufence-epar-product-information_hr.pdf)

íslenska (IS) (372.94 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/is/documents/product-information/cufence-epar-product-information_is.pdf)

italiano (IT) (395.01 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/it/documents/product-information/cufence-epar-product-information_it.pdf)

latviešu valoda (LV) (410.25 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/lv/documents/product-information/cufence-epar-product-information_lv.pdf)

lietuvių kalba (LT) (449.86 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/lt/documents/product-information/cufence-epar-product-information_lt.pdf)

magyar (HU) (436.93 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/hu/documents/product-information/cufence-epar-product-information_hu.pdf)

Malti (MT) (477.76 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/mt/documents/product-information/cufence-epar-product-information_mt.pdf)

Nederlands (NL) (192.92 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/nl/documents/product-information/cufence-epar-product-information_nl.pdf)

norsk (NO) (284.82 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/no/documents/product-information/cufence-epar-product-information_no.pdf)

polski (PL) (421.29 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/pl/documents/product-information/cufence-epar-product-information_pl.pdf)

português (PT) (397.13 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/pt/documents/product-information/cufence-epar-product-information_pt.pdf)

română (RO) (392.75 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/ro/documents/product-information/cufence-epar-product-information_ro.pdf)

slovenčina (SK) (420.04 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/sk/documents/product-information/cufence-epar-product-information_sk.pdf)

slovenščina (SL) (394.35 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/sl/documents/product-information/cufence-epar-product-information_sl.pdf)

Suomi (FI) (373.16 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/fi/documents/product-information/cufence-epar-product-information_fi.pdf)

svenska (SV) (375.12 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

02/07/2025

[View](/sv/documents/product-information/cufence-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0020 25/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Cufence : EPAR - All authorised presentations

English (EN) (43.59 KB - PDF)

**First published:** 29/07/2019

**Last updated:** 12/12/2023

[View](/en/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-436)

български (BG) (48.75 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/bg/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_bg.pdf)

español (ES) (39.74 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/es/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_es.pdf)

čeština (CS) (47.49 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/cs/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (40.87 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/da/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (39.05 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/de/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (40.21 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/et/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (54.67 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/el/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_el.pdf)

français (FR) (39.85 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/fr/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (108.67 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/hr/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (38.2 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/is/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_is.pdf)

italiano (IT) (39.8 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/it/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (48.61 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/lv/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (57.8 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/lt/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (54.8 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/hu/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (56.56 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/mt/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (39.94 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/nl/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (40.8 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/no/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_no.pdf)

polski (PL) (58.58 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/pl/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_pl.pdf)

português (PT) (40.37 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/pt/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_pt.pdf)

română (RO) (48.45 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/ro/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (54.16 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/sk/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (55.67 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/sl/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (40 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/fi/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (38.5 KB - PDF)

**First published:**

29/07/2019

**Last updated:**

12/12/2023

[View](/sv/documents/all-authorised-presentations/cufence-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Cufence Active substance trientine dihydrochloride International non-proprietary name (INN) or common name trientine dihydrochloride Therapeutic area (MeSH) Hepatolenticular Degeneration Anatomical therapeutic chemical (ATC) code A16A

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Cufence is indicated for the treatment of Wilson's disease in patients intolerant to D-Penicillamine therapy, in adults and children aged 5 years or older.

## Authorisation details

EMA product number EMEA/H/C/004111 Marketing authorisation holder

Univar Solutions BV

Schouwburgplein 30-34

Opinion adopted 29/05/2019 Marketing authorisation issued 25/07/2019 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Cufence : EPAR - Procedural steps taken and scientific information after authorisation

Reference Number: EMA/115243/2020

English (EN) (166.24 KB - PDF)

**First published:** 11/12/2019

**Last updated:** 02/07/2025

[View](/en/documents/procedural-steps-after/cufence-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Cufence : Orphan designation withdrawal assessment report (initial authorisation)

Adopted

Reference Number: EMA/342173/2019

English (EN) (148.96 KB - PDF)

**First published:** 29/07/2019

[View](/en/documents/orphan-maintenance-report/cufence-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf)

Cufence : EPAR - Public assessment report

Adopted

Reference Number: EMA/330602/2019

English (EN) (2.67 MB - PDF)

**First published:** 29/07/2019

[View](/en/documents/assessment-report/cufence-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Cufence

Adopted

Reference Number: EMA/290870/2019

English (EN) (68.98 KB - PDF)

**First published:** 29/05/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-cufence_en.pdf)

#### News on Cufence

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-29 May 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-29-may-2019) 29/05/2019

#### More information on Cufence

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-03-172) on 24 October 2003.

Cufence was withdrawn from the Community register of orphan medicinal products in June 2019 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 02/07/2025

## Share this page

[Back to top](#main-content)